Agios Announces Data from Dose-Escalation Phase 1 Study of AG-120 in Patients with IDH1 Mutant Positive Advanced Solid Tumors
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq futures drop over 1% as AI worries resurface, oil climbs
- Oil jumps on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
| AGIOS PHARM (NASDAQ: AGIO) | Delayed: 37.18 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $37.18 | 52 Week High | $71.49 | |||
| Open | $37.18 | 52 Week Low | $33.50 | |||
| Day High | $37.18 | P/E | N/A | |||
| Day Low | $37.18 | EPS | $-1.18 | |||
| Volume | 19,070 | |||||
